+91-8668442535

Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug Type (Oral Contraceptive, Ovulation Inducing Agents, Facial Hair Growth Inhibitor, Insulin Sensitizing Agent) - Growth, Future Prospects & Competitive Analysis, 2017- 2025

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. The polycystic ovarian syndrome (PCOS) therapeutics market is rapidly growing due to factors such as growing prevalence, changing lifestyle patterns, early diagnosis, and significant unmet needs.

The report titled "Polycystic ovarian syndrome (PCOS) Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall PCOS therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

Geographically, the global PCOS therapeutics market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of LATAM

Middle East and Africa

  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global polycystic ovarian syndrome (PCOS) therapeutics market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive landscape of the global polycystic ovarian syndrome (PCOS) therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global polycystic ovarian syndrome (PCOS) therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global polycystic ovarian syndrome (PCOS) therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global polycystic ovarian syndrome (PCOS) therapeutics market is segmented as follows:

  • Oral Contraceptive
  • Ovulation-inducing agents
  • Inhibitor of Facial Hair Growth
  • Insulin Sensitizing Substance
  • Other

Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting approximately 10 percent of women of reproductive age. Women with PCOS may have irregular or absent menstrual cycles, as well as high levels of male hormones. There is no cure for PCOS, but treatment focuses on managing its symptoms, such as infertility, hirsutism, acne, and obesity. Changes in lifestyle, an increase in the prevalence of PCOS, and rising treatment awareness are prime factors that drive the growth of the PCOS therapeutics market globally.

The PCOS therapeutics market is segmented for the purposes of the study based on drug types, such as oral contraceptives, ovulation-inducing agents, facial hair growth inhibitors, insulin sensitizing agents, and other therapeutics. Currently, oral contraceptives are the major revenue contributor because they are preferred as a first-line treatment option. Oral contraceptives are effective in regulating PCOS symptoms, such as the reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the skin, and regulating periods.

For the purpose of this study, the global polycystic ovarian syndrome (PCOS) therapeutics market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

According to the National Institutes of Health (NIH), PCOS affects 8 to 20 percent of reproductive-age women worldwide. In the base year 2016, North America dominated the polycystic ovarian syndrome (PCOS) therapeutics market. The United States was the largest revenue contributor due to the higher number of targeted populations, higher cost of therapeutics, more diverse lifestyle patterns, and higher treatment awareness among the general population.

According to the National Institutes of Health (NIH), PCOS affects more than 5 percent of women in the United States. On the other hand, the rapid evolution of healthcare infrastructure, an increase in the number of target populations, increased treatment awareness among the general population, and increased penetration of major market players will result in Asia-Pacific experiencing the fastest growth rate.

Frequently Asked Question:

The market for Polycystic Ovarian Syndrome Therapeutics Market is expected to reach USD$ 1,162.1 Mn in 2025.

The Polycystic Ovarian Syndrome Therapeutics Market is expected to see significant CAGR growth over the coming years, at 4.47%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Sharp Corporation, Honeywell International, Inc., LG Electronics Inc., Camfil AB, Whirlpool Corporation, AllerAir Industries, Inc., Blueair AB. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2017
Category:  Pharmaceuticals
Report ID:   58764
Report Format:   PDF
Pages:   120
Rating:    4.8 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support